Pharmacodynamic modeling of chemotherapeutic effects: application of a transit compartment model to characterize methotrexate effects in vitro.
about
Novel in vitro and mathematical models for the prediction of chemical toxicityImplementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical ResearchLifespan based pharmacokinetic-pharmacodynamic model of tumor growth inhibition by anticancer therapeuticsMethotrexate for topical application in an extemporaneous preparation.Fluoxetine reverses the memory impairment and reduction in proliferation and survival of hippocampal cells caused by methotrexate chemotherapy.Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systemsDifferential pharmacodynamic effects of paclitaxel formulations in an intracranial rat brain tumor model.A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis.A Predictive Mathematical Modeling Approach for the Study of Doxorubicin Treatment in Triple Negative Breast CancerTwo-mechanism peak concentration model for cellular pharmacodynamics of Doxorubicin.Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamicsMechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells.Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cellsPreclinical Modeling of Tumor Growth and Angiogenesis Inhibition to Describe Pazopanib Clinical Effects in Renal Cell Carcinoma.Systems pharmacological analysis of paclitaxel-mediated tumor priming that enhances nanocarrier deposition and efficacyTranslational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib.Development of a preclinical PK/PD model to assess antitumor response of a sequential aflibercept and doxorubicin-dosing strategy in acute myeloid leukemiaDeveloping Exposure/Response Models for Anticancer Drug Treatment: Special ConsiderationsTranslational modeling and simulation approaches for molecularly targeted small molecule anticancer agents from bench to bedside.Quantitative characterization of in vitro bystander effect of antibody-drug conjugates.Biomarker- versus drug-driven tumor growth inhibition models: an equivalence analysis.Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity.Current mathematical models for cancer drug discovery.Calculated Log D Is Inversely Correlated With Select Camptothecin Clearance and Efficacy in Colon Cancer Xenografts.Cell cycle checkpoint models for cellular pharmacology of paclitaxel and platinum drugs.Cell Signaling Model Connects Vorinostat Pharmacokinetics and Tumor Growth Response in Multiple Myeloma Xenografts.General relationship between transit compartments and lifespan models.Utility of a Novel Three-Dimensional and Dynamic (3DD) Cell Culture System for PK/PD Studies: Evaluation of a Triple Combination Therapy at Overcoming Anti-HER2 Treatment Resistance in Breast Cancer.Quantitative translational modeling to facilitate preclinical to clinical efficacy & toxicity translation in oncology.
P2860
Q26851492-C363773E-EC48-449E-8A66-A9D02AADA109Q27024682-DB15D3F8-B555-4C89-985A-29A7F984B59AQ28543966-89D60FE9-FE7C-4D94-9DB6-19D485E6C3A3Q30316265-B8BE5A84-8CF6-4DCF-BAA7-6F9570DC12F7Q30499383-B6C8F0B0-D9F8-4066-8A95-B27FCEF842B1Q33611516-781B44D1-113E-4273-AD55-7946B1117FC1Q33613579-905E9FD0-634D-4FB3-92FB-D67F64D13FA4Q33729213-86C75A08-9715-4BD8-8AD3-68271CA96678Q33916210-72169961-781A-4812-8F3E-B42A5EF0776DQ34768920-464B914A-4E16-4A39-9A76-1950E5803B4FQ35919697-E4956BA9-09B1-47BA-B7DB-37E139B169C5Q36094941-764C7FA5-AA5A-4673-B02B-BD38C8875FDFQ36447737-FC7538C2-EFEF-4E64-B644-C3C2E0EC540DQ36473115-E28A8F7A-E051-4D77-B94F-8A225CB55E65Q36497582-EFF359DC-AA62-41B9-8728-074CFEE73EEAQ36910546-21E7E823-313A-4771-BC9F-3F8FF12203AAQ36951941-9BACE58B-E8D8-4A6D-AC13-D8CB19EA090AQ38557331-AB857134-EDE6-42C5-92A2-0118DD6A778CQ38707936-A74B2405-B2BC-4051-84B0-141655B7E26BQ38817525-86556116-04B0-4B6D-9719-BBA218A79514Q38849422-DFE7FE23-DEEC-4498-B5B8-F5619B01165FQ38962519-773399DF-E60D-4571-91A1-C17A8C58486DQ39359967-F960344A-9318-40D1-9C0E-D843F94C8D0FQ39673267-F8714D54-D8D3-400D-9DF4-D2D10F55E51BQ39986942-12A64916-1C2A-4670-A105-E19AB26351FFQ47633998-79670336-40CA-4574-BBB5-91B6516D7520Q51351388-99BD277F-59D6-4E84-86D9-5F4C2E468684Q54979012-B7DCE9C8-3AC4-48A0-ACF5-5F7250396CF6Q55329667-E360A924-9264-456B-9EC5-D27B841B176E
P2860
Pharmacodynamic modeling of chemotherapeutic effects: application of a transit compartment model to characterize methotrexate effects in vitro.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Pharmacodynamic modeling of ch ...... methotrexate effects in vitro.
@en
type
label
Pharmacodynamic modeling of ch ...... methotrexate effects in vitro.
@en
prefLabel
Pharmacodynamic modeling of ch ...... methotrexate effects in vitro.
@en
P2860
P356
P1433
P1476
Pharmacodynamic modeling of ch ...... methotrexate effects in vitro.
@en
P2093
Evelyn D Lobo
Joseph P Balthasar
P2860
P356
10.1208/PS040442
P577
2002-01-01T00:00:00Z